Summary of Study ST000924
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000640. The data can be accessed directly via it's Project DOI: 10.21228/M8Z40Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000924 |
| Study Title | MuRF1-Related Metabolic Alterations in HL-1 Cardiomyocyte Induced by Cyclic Stretch |
| Study Type | Cardiomyocyte cell culture |
| Study Summary | We collected cell media and performed GC-MS non-targeted metabolomics to identify the role of MuRF1 in the dynamic metabolic changes in cardiomyocytes. |
| Institute | University of North Carolina at Chapel Hill |
| Department | Pathology & Laboratory Medicine |
| Laboratory | Willis |
| Last Name | Willis |
| First Name | Monte |
| Address | 111 Mason Farm Road |
| monte_willis@med.unc.edu | |
| Phone | 9849995431 |
| Submit Date | 2017-10-30 |
| Num Groups | 6 |
| Total Subjects | 32 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2018-12-11 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000976 |
| Treatment Summary: | Cell culture, adenovirus transduction, and MuRF1 knock-down. The cardiomyocyte-derived HL-1 cell line was maintained as previously described [11-13]. Briefly, cells were split and cultured to ~90% confluency in 6-well BioFlex culture plates (Flexcell International Corporation, Hillsborough, NC) coated with 0.02% gelatin (wt/vol) and 0.5% fibronectin (vol/vol) for ∼30 min and grown in complete Claycomb media containing 10% serum (Cat. #51800C, Sigma-Aldrich; St. Louis, MO), as previously described [13]. Media was changed to serum-free Dulbecco’s modified Eagle’s medium (DMEM) supplemented 1% penicillin-streptomycin. HL-1 cells were transduced with 30 MOI adenovirus expressing shRNA MuRF1 (Ad.shRNA MuRF1) or shRNA scramble (Ad.shRNA Scr) control (custom made by Vector Biolabs, Philadelphia, PA) to transiently knock down MuRF1, as previously described [13]. |
| Treatment: | Ad.shRNA MuRF1 (or Ad.shRNA Scramble) treatment |
| Treatment Compound: | Adenovirus |
| Treatment Route: | Media |
| Treatment Dose: | 30 MOI |
| Treatment Dosevolume: | <10 ul |
| Treatment Doseduration: | 48 hours |
| Treatment Vehicle: | DMEM |
| Cell Media: | DMEM / No serum |
| Cell Envir Cond: | Stretch |
| Cell Pct Confluence: | ~60% |
| Cell Media Lastchanged: | At start of stretch period. |
